DTRA amends vaccine production solicitations

The U.S. Department of Defense recently issued an amendment to its solicitation for the development of various vaccine prototypes.

The DOD's Defense Threat Reduction Agency, in conjunction with the Joint Science and Technology Office for Chemical & Biological Defense, announced an amendment to BAA Solicitation HDTRA-12-CHEM-BIO-BAA, governing the solicitation of white papers and full proposals, according to Virtual-Strategy.com.

The amendment covers proposals for the development of biomanufacturing processes that use flexible and agile technologies and methods for the production of cost-effective, rapidly-produced sustainable supplies of the multiple and diverse vaccines needed by the military.

The DTRA is seeking plan proposals for the development of vaccine prototypes that use technologies such as high-yield expression platforms and high-capacity and broadly applicable recovery and purification systems.

Vaccine prototypes are also sought that maximize the utilization of scalable, single-use manufacturing systems designed to bring about reductions in project cycle times, Virtual-Strategy.com reports.

The goal of the amended solicitation is to achieve more rapid successful transitions through the development of optimized, well-characterized vaccine production processes with a level of control and flexibility that will allow for a multi-product facility that can supply several different U.S. Food and Drug Administration approved vaccines for use by the military.

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.